# OnCo record pod1um-201 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/pod1um-201/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "pod1um-201", "NCT03599713" ;
  schema:name "POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)"@en ;
  schema:alternateName "POD1UM-201"@en ;
  schema:description "The third PD-1 antibody tested in this rare and fast-growing skin cancer shrank it in more than half of the people who took it, and most of those responses lasted years. Six in ten were still alive three years later, in a disease that used to kill within months."@en ;
  schema:url <https://onco.cc/trials/pod1um-201/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03599713>, <https://doi.org/10.1136/jitc-2025-012478>, <https://pubmed.ncbi.nlm.nih.gov/40796223/> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/skin-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/retifanlimab/> ;
  onco:companies <https://onco.cc/companies/incyte/> ;
  onco:terms <https://onco.cc/terms/irae/>, <https://onco.cc/terms/mcpyv-status/>, <https://onco.cc/terms/tmb/> ;
  onco:trials <https://onco.cc/trials/javelin-merkel-200/>, <https://onco.cc/trials/keynote-017/>, <https://onco.cc/trials/admec-o/> .